[go: up one dir, main page]

ECSP22041860A - Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso - Google Patents

Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso

Info

Publication number
ECSP22041860A
ECSP22041860A ECSENADI202241860A ECDI202241860A ECSP22041860A EC SP22041860 A ECSP22041860 A EC SP22041860A EC SENADI202241860 A ECSENADI202241860 A EC SENADI202241860A EC DI202241860 A ECDI202241860 A EC DI202241860A EC SP22041860 A ECSP22041860 A EC SP22041860A
Authority
EC
Ecuador
Prior art keywords
generation
methods
fever virus
yellow fever
virus antibodies
Prior art date
Application number
ECSENADI202241860A
Other languages
English (en)
Inventor
Anna Wec
Laura Walker
Original Assignee
Mabloc Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabloc Llc filed Critical Mabloc Llc
Publication of ECSP22041860A publication Critical patent/ECSP22041860A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C07K16/116—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan anticuerpos y fragmentos de unión al antígeno de los mismos específicos para la proteína E de YFV y con potencia neutralizante contra YFV. Estos anticuerpos y fragmentos de unión al antígeno son útiles en el tratamiento de YFV.
ECSENADI202241860A 2019-11-25 2022-05-25 Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso ECSP22041860A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962940049P 2019-11-25 2019-11-25

Publications (1)

Publication Number Publication Date
ECSP22041860A true ECSP22041860A (es) 2022-09-30

Family

ID=74046131

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202241860A ECSP22041860A (es) 2019-11-25 2022-05-25 Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso

Country Status (14)

Country Link
US (3) US11479598B2 (es)
EP (1) EP4065601A1 (es)
JP (2) JP2023503347A (es)
KR (1) KR20220111289A (es)
CN (1) CN114867744B (es)
AU (1) AU2020394408A1 (es)
BR (1) BR112022010179A2 (es)
CA (1) CA3162718A1 (es)
CO (1) CO2022006909A2 (es)
EC (1) ECSP22041860A (es)
IL (1) IL293282A (es)
PE (1) PE20221865A1 (es)
WO (1) WO2021108448A1 (es)
ZA (1) ZA202205927B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114867744B (zh) 2019-11-25 2025-07-25 迈博洛克有限责任公司 抗黄热病病毒抗体及其产生和使用方法
CN113683690B (zh) * 2021-08-19 2023-05-23 中国科学院微生物研究所 针对黄热病毒ns1蛋白的抗体及其应用
WO2023034566A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Anti-dll3 antibodies and uses thereof
WO2023039437A1 (en) * 2021-09-07 2023-03-16 Mabloc, Llc Anti-sars-cov-2 antibody compositions and uses thereof
WO2024039298A1 (en) * 2022-08-17 2024-02-22 Agency For Science, Technology And Research Anti-yellow fever virus antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
CA2746964C (en) 2009-01-14 2018-07-24 Marie-Paule Lucienne Armanda Bouche Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP3205670A1 (en) 2009-06-05 2017-08-16 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
CN106589116B (zh) * 2016-12-06 2020-01-03 中国科学院微生物研究所 一种黄病毒人源单克隆抗体及应用
CN110343174B (zh) * 2018-04-04 2021-05-04 中国科学院微生物研究所 一种高亲和力的黄热病毒人源单克隆抗体及其应用
CN113651885B (zh) * 2018-04-04 2022-04-15 中国科学院微生物研究所 一种高灵敏度的黄热病毒人源单克隆抗体及其应用
CN110343173B (zh) * 2018-04-04 2021-05-04 中国科学院微生物研究所 一种高功能活性的黄热病毒人源单克隆抗体及其应用
WO2019200160A1 (en) * 2018-04-11 2019-10-17 Tychan Pte. Ltd. Methods and compositions for treating yellow fever
CN114867744B (zh) 2019-11-25 2025-07-25 迈博洛克有限责任公司 抗黄热病病毒抗体及其产生和使用方法

Also Published As

Publication number Publication date
CO2022006909A2 (es) 2022-08-19
AU2020394408A1 (en) 2022-06-09
CN114867744A (zh) 2022-08-05
US20210253675A1 (en) 2021-08-19
ZA202205927B (en) 2023-11-29
PE20221865A1 (es) 2022-12-02
KR20220111289A (ko) 2022-08-09
US20240218054A1 (en) 2024-07-04
US11479598B2 (en) 2022-10-25
JP2025121907A (ja) 2025-08-20
WO2021108448A1 (en) 2021-06-03
BR112022010179A2 (pt) 2022-08-30
JP2023503347A (ja) 2023-01-27
EP4065601A1 (en) 2022-10-05
CA3162718A1 (en) 2021-06-03
US20230203135A1 (en) 2023-06-29
CN114867744B (zh) 2025-07-25
JP7732118B2 (ja) 2025-09-01
IL293282A (en) 2022-07-01
US12110319B2 (en) 2024-10-08

Similar Documents

Publication Publication Date Title
CO2022006909A2 (es) Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso
PH12020550650A1 (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
CO2019012210A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
MX2021013355A (es) Composiciones de proteínas de fusión quiméricas modificadas y métodos de uso de las mismas.
MX2021004270A (es) Anticuerpos estabilizadores de trem2.
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
MX2020000342A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos.
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
CR20180142A (es) ANTICUERPOS ANTI-FAP Y MÉTODOS DE USO(Divisional Exp: 2013-0038)
MX393951B (es) Anticuerpos antisortilina y métodos para su uso.
MX2022003517A (es) Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco.
MX2017001599A (es) Anticuerpos novedosos y sus usos.
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
BR112021015477A2 (pt) Anticorpos anti-cd228 e conjugados anticorpo-fármaco
MX2024010593A (es) Anticuerpos 3e10 humanizados, variantes y fragmento de unión al antígeno de los mismos
MX2020013428A (es) Anticuerpos monoclonales contra inmunoglobulina de celulas t y molecula que contiene dominio de mucina-3 (tim-3) humana.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2021003119A (es) Anticuerpos anti-klrg1.
WO2020036646A3 (en) Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy
UY37752A (es) Proteínas de unión al antígeno anti-jagged1
PE20171734A1 (es) Anticuerpos monoclonales especificos del antigeno m del virus metapneumovirus humano (hmpv) y su uso en un metodo de diagnostico
CL2019002642A1 (es) Anticuerpos de hantavirus andes y métodos de uso de los mismos.
AR133072A2 (es) Anticuerpos aislados o fragmentos aislados de unión a antígeno de los mismos que se unen al receptor de leptina humana (lepr) y activan la señalización lepr
AR115992A2 (es) Proteínas de unión a antígeno que activan el receptor de leptina